JP2005529965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529965A5 JP2005529965A5 JP2004514763A JP2004514763A JP2005529965A5 JP 2005529965 A5 JP2005529965 A5 JP 2005529965A5 JP 2004514763 A JP2004514763 A JP 2004514763A JP 2004514763 A JP2004514763 A JP 2004514763A JP 2005529965 A5 JP2005529965 A5 JP 2005529965A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- compound
- independently
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0214139.8A GB0214139D0 (en) | 2002-06-19 | 2002-06-19 | Chemical compounds |
| PCT/EP2003/006417 WO2004000785A2 (en) | 2002-06-19 | 2003-06-18 | Phenyloxyalkanonic acid derivatives as hppar activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529965A JP2005529965A (ja) | 2005-10-06 |
| JP2005529965A5 true JP2005529965A5 (enExample) | 2006-03-16 |
Family
ID=9938907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004514763A Pending JP2005529965A (ja) | 2002-06-19 | 2003-06-18 | ｈＰＰＡＲ活性化物質としてのフェニルオキシアルカン酸誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7241793B2 (enExample) |
| EP (1) | EP1513796B1 (enExample) |
| JP (1) | JP2005529965A (enExample) |
| AT (1) | ATE386012T1 (enExample) |
| AU (1) | AU2003237955A1 (enExample) |
| DE (1) | DE60319080T2 (enExample) |
| ES (1) | ES2300587T3 (enExample) |
| GB (1) | GB0214139D0 (enExample) |
| WO (1) | WO2004000785A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| JPWO2005095364A1 (ja) * | 2004-03-30 | 2008-02-21 | 第一三共株式会社 | フェノキシ酢酸誘導体及びそれを用いた医薬 |
| JP2007230868A (ja) * | 2004-03-30 | 2007-09-13 | Dai Ichi Seiyaku Co Ltd | 二環性化合物及びそれを用いた医薬 |
| DE102004016845A1 (de) * | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
| AU2005238163A1 (en) * | 2004-04-28 | 2005-11-10 | F. Hoffmann-La Roche Ag | Pyrazole phenyl derivatives as PPAR activators |
| JP2007284352A (ja) * | 2004-08-05 | 2007-11-01 | Dai Ichi Seiyaku Co Ltd | ピラゾール誘導体 |
| CN100383131C (zh) * | 2005-06-15 | 2008-04-23 | 浙江大学 | 2-对三氟甲苯-4-甲基-5-噻唑甲酸乙酯的合成方法 |
| WO2007037010A1 (ja) * | 2005-09-29 | 2007-04-05 | Daiichi Pharmaceutical Co., Ltd. | フェノキシ酢酸誘導体及びそれを用いた医薬 |
| CA2626443A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Oxazole and thiazole ppar modulators |
| CA2626483A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Compounds and compositions as ppar modulators |
| DE602007008742D1 (de) * | 2006-09-15 | 2010-10-07 | Pfizer | Substituierte pyridylmethylbicyclocarboxyamidverbindungen |
| EP2091926B1 (en) * | 2006-11-13 | 2015-10-21 | Novartis AG | Substituted pyrazole and triazole compounds as ksp inhibitors |
| CN110269856A (zh) * | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| KR20150130405A (ko) | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | 트롬빈의 억제제로서의 할로게노피라졸 |
| RU2678830C2 (ru) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| HK1246164A1 (zh) | 2015-02-27 | 2018-09-07 | Verseon Corporation | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US11753403B2 (en) | 2020-03-03 | 2023-09-12 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506757B1 (en) * | 1998-03-10 | 2003-01-14 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| US6723743B1 (en) * | 1999-09-28 | 2004-04-20 | Neurogen Corporation | High affinity small molecule C5a receptor modulators |
| PE20011010A1 (es) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| AU2001277723A1 (en) * | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
| EP1322309B1 (en) * | 2000-09-29 | 2008-08-13 | Neurogen Corporation | High affinity small molecule c5a receptor modulators |
| GB0029974D0 (en) | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
| GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
-
2002
- 2002-06-19 GB GBGB0214139.8A patent/GB0214139D0/en not_active Ceased
-
2003
- 2003-06-18 AU AU2003237955A patent/AU2003237955A1/en not_active Abandoned
- 2003-06-18 DE DE60319080T patent/DE60319080T2/de not_active Expired - Fee Related
- 2003-06-18 JP JP2004514763A patent/JP2005529965A/ja active Pending
- 2003-06-18 AT AT03735642T patent/ATE386012T1/de not_active IP Right Cessation
- 2003-06-18 US US10/518,347 patent/US7241793B2/en not_active Expired - Fee Related
- 2003-06-18 EP EP03735642A patent/EP1513796B1/en not_active Expired - Lifetime
- 2003-06-18 WO PCT/EP2003/006417 patent/WO2004000785A2/en not_active Ceased
- 2003-06-18 ES ES03735642T patent/ES2300587T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529965A5 (enExample) | ||
| JP2004532266A5 (enExample) | ||
| JP2009531280A5 (enExample) | ||
| RU2016103139A (ru) | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления | |
| JP2009528375A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2004517100A5 (enExample) | ||
| JP2010502730A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2004518702A5 (enExample) | ||
| JP2007523155A5 (enExample) | ||
| JP2004534035A5 (enExample) | ||
| JP2003502369A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| JP2005507872A5 (enExample) | ||
| JP2007502817A5 (enExample) | ||
| JP2006524252A5 (enExample) | ||
| JP2009528275A5 (enExample) | ||
| JP2007500222A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2007531764A5 (enExample) | ||
| JP2010535706A5 (enExample) | ||
| JP2020520949A5 (enExample) |